Randomized phase III trial comparing adjuvant S-1 to capecitabine in stage III colorectal cancer (JCOG0910, CRC Adj-CAPS)
- Conditions
- Stage III colorectal cancer
- Registration Number
- JPRN-UMIN000003272
- Lead Sponsor
- Japan Clinical Oncology Group(JCOG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1550
Not provided
1) Body temperature is higher than 38 degrees centigrade at registration. 2) Infections which needs systemic treatment. 3) Active co-existing malignancy (synchronous or metachronous malignancy whose disease-free period is within 5 years). Carcinoma in situ is eligible. 4) Severe postoperative complicatoins which do not resolve until registration. 5) Regularly using phenytoin or warfarin potassium. 6) Pregnant or breast-feeding woman. 7) Difficult to participate in the trial due to mentel disorder or psychiatric symptoms. 8) Systemic steroids medication. 9) Uncontrollable diabetes mellitus. 10) Uncontrollable hypertension. 11) History of severe heart disease, heart failure, myocardial infarction within the past 6 months or attack of angina pectoris within the past 6 months.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method